Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Emerging Research on the Use of Psychedelics in the Treatment of Mental Illness

In the last 30 years, revived interest in the application of psychedelic compounds in psychiatry has created a huge body of scientific knowledge on the pharmacological and therapeutic action of...

Course Authors

Danilo De Gregorio, PharmD, Ph.D.

Dr. De Gregorio is Assistant Professor of Pharmacology, Division of Neuroscience, Vita-Salute San Raffaele University, Milan, Italy.

Within the past 12 months, Dr. De Gregorio has been a consultant to Diamond Therapeutics Inc., Toronto, Canada.

Albert Einstein College of Medicine, Montefiore Medical Center, CCPD staff and interMDnet staff have nothing to disclose relevant to this activity.

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Enumerate the different psychedelics available and their potential use in mental health;

  • Describe the beneficial outcomes and long-term effects of the psychedelics;

  • Highlight the potential side effects due to the use of psychedelics in mental health.



The opinions expressed herein are those of the author(s) and do not necessarily represent the views of Einstein-Montefiore or InterMDnet. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.


Please click below to accept the terms of this CME activity

Courses You Might Like

The Impact of COVID-19 on Mental Health

The coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization (W.H.O.) on March 11, 2020. China was the first country that identified the novel coronavirus as the cause of the pandemic. Globally, as of May 25, 2020, the number of confirmed cases was 5,525,299, the number of deaths was 347,110 and the number of recovered cases was 2,316,127. The challenges of COVID-19 pandemic include the following issues: modified lifestyle due to lockdown and
Authors: Roger Ho M.D., F.R.C.Psych., F.R.C.P.C., and Cyrus Ho M.B.B.S., M.R.C.Psych.
Estimated Time: 1 Hour

Molecular Mechanisms of Cognitive Deficits in Schizophrenia

Schizophrenia is a severe mental disorder characterized by three main symptom domains: positive, negative and cognitive. While positive symptoms such as hallucinations and delusions are largely responsive to antipsychotic medication, negative symptoms like anhedonia, and cognitive symptoms such as memory and attentional deficits, constitute a major unmet therapeutic need. Cognitive symptoms, in particular, have been the focus of substantial on-going clinical and preclinical research as cognitive impairment is highly predictive of long-term functional outcome in patients.
Authors: Sarah Canetta, Ph.D., and Christoph Kellendonk, Ph.D.
Estimated Time: 1 Hour

PTSD: Current Therapies

Childhood abuse, motor vehicle accidents, assault, and other psychological traumas and stressors represent a major public health problem in our society today. Psychological trauma, defined as threat to life or integrity of yourself or someone close to you, affects over half of the U.S. population at some time in their lives. Childhood sexual abuse alone affects 16% of women (about 40 million) in the U.S.A. The most common cause of post traumatic stress disorder (PTSD) in women is
Authors: J. Douglas Bremner, M.D.
Estimated Time: 1 Hour

Current and Emerging Therapies for Relapsing-Remitting Multiple Sclerosis

This presentation may include discussion of commercial products and services. Dr. Miller will discuss unapproved therapies for MS including daclizumab, ocrelizumab, sphingosine-1-phosphate receptor molecules and ofatumumab. The modern era of disease modifying therapy (DMT) in multiple sclerosis (MS) began in 1993 with the introduction of interferon beta-1b for the treatment of relapsing-remitting multiple sclerosis (RMMS). Since then, the U.S. Food and Drug Administration (FDA) has approved eight new unique therapeutic agents (actually nine products). In other parts
Authors: Aaron Miller, M.D..
Estimated Time: 1 Hour

Glial Cells

Astrocyte: Astrocytes are a type of non-neuronal cell in the central nervous system that exhibit a wide variety of cellular properties and shapes. These cells are involved in a broad range of functions in disease and normal brain function. Microglia: Microglia are the immune system cells of the central nervous system, but they also help remodel synapses in response to neural activity. Oligodendrocyte: Oligodendrocytes form the multi-laminar myelin electrical insulation on axons in the
Authors: R. Douglas Fields, Ph.D.
Estimated Time: 1 Hour

The Management of Major Depression During Pregnancy

Susan has a history of severe recurrent depressive episodes with debilitating panic attacks beginning at age 14. She has been tried on all currently available SSRI medications, as well as buproprion, mirtazapine and serezone. She has been successfully treated with paroxetine for the last three years and was either unable to tolerate or did not respond to the previous medication trials. She presents asking for treatment advice during pregnancy. How should her psychiatrist approach weighing the risks and
Authors: Jennifer L. Payne, M.D.
Estimated Time: 1 Hour